Epigenomics AG Successfully Completes Larger Clinical Study in Early Lung Cancer Detection

BERLIN and SEATTLE, June 18, 2008 (PRIME NEWSWIRE) -- Epigenomics AG (Frankfurt:ECX), a molecular diagnostics company focusing on the development and commercialization of products for cancer detection based on DNA methylation, today announced that it successfully completed a larger clinical study in its lung cancer program. The study was run in close collaboration with Prof. Dr. Christian Witt and Dr. Bernd Schmidt at the Charite University Hospital in Berlin, Germany.

MORE ON THIS TOPIC